Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Royalties	$ 6,606	$ 5,241	$ 16,893	$ 13,091
Material sales	10,681	3,476	14,410	9,191
Collaborative research and development and other revenues	1,131	1,891	1,717	4,284
Total revenues	18,418	10,608	33,020	26,566
Operating costs and expenses:
Cost of goods	2,600	1,186	3,673	3,637
Research and development	4,010	2,689	7,972	5,821
General and administrative	7,225	5,239	13,219	10,310
Lease exit and termination costs	218	136	441	340
Total operating costs and expenses	14,053	9,250	25,305	20,108
Income from operations	4,365	1,358	7,715	6,458
Other (expense) income:
Interest expense, net	(2,969)	(181)	(5,945)	(429)
Increase in contingent liabilities	(7,274)	(1,312)	(7,277)	(3,260)
Gain on deconsolidation of Viking Therapeutics	28,190	0	28,190	0
Equity in net losses from Viking Therapeutics	(870)	0	(870)	0
Other, net	850	1,376	404	621
Total other (expense) income, net	17,927	(117)	14,502	(3,068)
Income before income taxes	22,292	1,241	22,217	3,390
Income tax (expense) benefit	(265)	47	(279)	(6)
Net income including noncontrolling interests:	22,027	1,288	21,938	3,384
Less: Net loss attributable to noncontrolling interests	(1,537)	(304)	(2,380)	(304)
Net income	$ 23,564	$ 1,592	$ 24,318	$ 3,688
Per share amounts attributable to Ligand common shareholders:
Basic net income per share (in usd per share)	$ 1.19	$ 0.08	$ 1.24	$ 0.18
Diluted net income per share (in usd per share)	$ 1.11	$ 0.07	$ 1.16	$ 0.17
Weighted average number of common shares-basic (in shares)	19,725,410	20,738,299	19,668,183	20,668,110
Weighted average number of common shares-diluted (in shares)	21,276,404	21,780,034	20,953,134	21,776,125